These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 16161254)

  • 1. Effects of atenolol and propanolol on platelet aggregation in moderate essential hypertension.
    Beyan C; Kaptan K; Ifran A
    Croat Med J; 2005 Aug; 46(4):695-6; author reply 696-7. PubMed ID: 16161254
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of atenolol and propranolol on platelet aggregation in moderate essential hypertension: randomized crossover trial.
    Punda A; Polić S; Rumboldt Z; Bagatin J; Marković V; Lukin A
    Croat Med J; 2005 Apr; 46(2):219-24. PubMed ID: 15849842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
    Devereux RB; Dahlöf B
    Curr Med Res Opin; 2007 Feb; 23(2):443-57. PubMed ID: 17288698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet aggregation in hypertension and the effects of antihypertensive treatment.
    Nyrop M; Zweifler AJ
    J Hypertens; 1988 Apr; 6(4):263-9. PubMed ID: 2897988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of the antihypertensive effect of atenolol (ICI 66 082) and propranolol.
    Hansson L; Westerlund A; Aberg H; Karlberg BE
    Eur J Clin Pharmacol; 1976 Mar; 09(5-6):361-5. PubMed ID: 786662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of atenolol and losartan on baroreflex sensitivity and heart rate variability in uncomplicated essential hypertension.
    Chern CM; Hsu HY; Hu HH; Chen YY; Hsu LC; Chao AC
    J Cardiovasc Pharmacol; 2006 Feb; 47(2):169-74. PubMed ID: 16495752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Propranolol prevents the development of venous thrombosis in rats by a platelet-dependent mechanism.
    Gruszecki M; Rółkowski R; Pawlak R; Buczko W
    Pol J Pharmacol; 2001; 53(1):5-10. PubMed ID: 11785911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Anglo-Scandinavian Cardiac Outcomes Trial-- blood pressure lowering arm.
    Coleman JJ; Kendall MJ
    J Clin Pharm Ther; 2006 Aug; 31(4):299-307. PubMed ID: 16882098
    [No Abstract]   [Full Text] [Related]  

  • 9. [Atenolol, pindolol and propranolol in essential hypertension: response rate and tolerance].
    Greminger P; Vetter H; Boerlin HJ; Baumgart P; Havelka J; Walger P; Lüscher T; Siegenthaler W; Vetter W
    Schweiz Med Wochenschr; 1982 Dec; 112(50):1831-5. PubMed ID: 7156966
    [No Abstract]   [Full Text] [Related]  

  • 10. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
    Devereux RB; de Faire U; Fyhrquist F; Harris KE; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Hille DA; Dahlöf B
    Curr Med Res Opin; 2007 Feb; 23(2):259-70. PubMed ID: 17288679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical effectiveness of low-dose chlorthalidone (6.25 mg) + atenolol combination in stage I hypertensive patients: a multicenter, randomized, controlled study.
    Pareek A; Karnik N; Salagre SB; Zawar SD; Joglekar VK; Chandurkar N; Naik GS
    Curr Med Res Opin; 2008 Jun; 24(6):1771-9. PubMed ID: 18479589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A survey on the application of oral propranolol and atenolol for the management of infantile hemangiomas in mainland China: Survey on propranolol atenolol hemangiomas.
    Zhao ZL; Liu C; Wang QZ; Zhang WB; Shao L; Wu HW; Zheng JW
    Medicine (Baltimore); 2021 Jan; 100(1):e24146. PubMed ID: 33429792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of isradipine on platelet aggregation and oxygen free radicals in hypertension.
    Ding YA; Han CL; Chou TC; Lai WY; Shiao MF
    J Hypertens Suppl; 1991 Dec; 9(6):S370-1. PubMed ID: 1668009
    [No Abstract]   [Full Text] [Related]  

  • 14. [Hemodynamic effect of propranolol in permanent essential arterial hypertension].
    Weiss Y; London G; Maiz HB; Safar M; Milliez P
    Coeur Med Interne; 1974; 13(3):521-5. PubMed ID: 4434715
    [No Abstract]   [Full Text] [Related]  

  • 15. Increased platelet adhesion and aggregation in hypertensive patients: effect of atenolol.
    Markel A; Brook JG; Levy Y; Aviram M; Youdim MB
    Br J Clin Pharmacol; 1983 Dec; 16(6):663-8. PubMed ID: 6661351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The treatment of hypertension patients with Estulic].
    Baliakina EV; Anuchin VV; Patrusheva IF; Iurenev AP
    Ter Arkh; 1996; 68(12):57-60. PubMed ID: 9054043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential effects of nebivolol and atenolol on transmitral diastolic filling parameters in patients with essential hypertension.
    Tuncer M; Guntekin U; Gunes Y; Gumrukcuoglu HA; Eryonucu B
    Adv Ther; 2008 Jun; 25(6):619-26. PubMed ID: 18563311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of hypotensive and hypolipidemic effects of Catharanthus roseus leaves extract with atenolol on adrenaline induced hypertensive rats.
    Ara N; Rashid M; Amran MS
    Pak J Pharm Sci; 2009 Jul; 22(3):267-71. PubMed ID: 19553172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atenolol versus other beta-adrenergic blockers.
    Aursnes I; Osnes JB
    J Am Coll Cardiol; 2009 Jun; 53(22):2101-2; author reply 2106-7. PubMed ID: 19477363
    [No Abstract]   [Full Text] [Related]  

  • 20. [Cardiac protection of atenolol: want of proof].
    Shi ZW
    Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(13):928-30. PubMed ID: 16029536
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.